U
UltraSight
Real-time guidance and quality assessment to allow healthcare professionals to consistently perform high-quality cardiac ultrasound in a variety of settings
About UltraSight
UltraSight is a pioneering company in the medical technology sector, focusing on revolutionizing cardiac ultrasound through advanced machine learning. The company's core product is an AI-guided ultrasound system that aids healthcare professionals in making more accurate and timely clinical decisions. UltraSight's technology is designed to be used in various care settings, from doctors' offices and community hospitals to ambulances and remote communities, thereby increasing patient access to high-quality cardiac imaging. The business primarily serves healthcare providers, including hospitals, clinics, and emergency medical services, operating within the global healthcare market. UltraSight's business model involves selling its AI-guided ultrasound systems and software subscriptions to medical institutions. The company generates revenue through direct sales, partnerships, and collaborations with major healthcare providers and technology companies, such as GE Healthcare. By leveraging machine learning and AI, UltraSight aims to democratize access to advanced cardiac care, making it more widely available and improving patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Rehovot, Israel
- Employees
- 42
- Open positions
- None listed
- Dealroom signal
- 76.8/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Cardiology and cardiovascular, Spinout, Tech for Hospitals and Clinics, Tech for Medical Professionals, AI for medical imaging, Physician Support Tools, Hard Tech, DT and LS
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2023 | $0 | — | SELVAS Healthcare (Formerly Hana Must Second Special Purpose Acquisition Company) | ↗ |
| SPINOUT✓Other financing | Aug 2022 | $0 | — | Weizmann Institute of Science | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for UltraSight is 1.8K monthly website visits, up 63.6% over the last three months. UltraSight's team grew 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Yozma Group
Atain specialty insurance company
Weizmann Institute of Science
Series B and later1 investor entered at this stage
SELVAS Healthcare (Formerly Hana Must Second Special Purpose Acquisition Company)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about UltraSight on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See UltraSight’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.